Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Adding Asciminib to the Standard-of-care for Post Allogenic Hematopoietic Stem-cell Transplant (HSCT) Maintenance in Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (Ph+ B-ALL) or Blastic Transformed CML (Myeloid or Lymphoid) (CML-BP)

NCT07493408 is registered in ClinicalTrials.gov with The University of Hong Kong as lead sponsor.

NCT NCT07493408
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07493408 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Adding Asciminib to the Standard-of-care for Post Allogenic Hematopoietic Stem-cell Transplant (HSCT) Maintenance in Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (Ph+ B-ALL) or Blastic Transformed CML (Myeloid or Lymphoid) (CML-BP)
Lead sponsor
The University of Hong Kong
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 30, 2026
Completion date
December 31, 2037
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

blastic transformation of chronic myeloid leukemia, haematopoietic stem cell transplant, allogeneic, ph+ acute lymphoblastic leukemia (ph+all), philadelphia chromosome-positive b-cell acute lymphoblastic leukemia (ph+ b-all)